Suppliers / Aarti Pharmalabs

Aarti Pharmalabs

India AARTIPHARM.BO Updated 9 July 2026

Aarti Pharmalabs is an API manufacturer based in India. It holds 41 active US drug master files. Its GMP standing is certified by CDSCO (India) and US FDA. Its most recent recorded inspection, by US FDA, closed on 27 March 2026 as VAI. Customs aggregates show $125.7M of exports covering 1,582 molecules to 72 destinations in 2025.

41
active US DMFs
0
valid CEPs
4
registered plants 2 with an FDA FEI number
4
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 March 2026 VAI US FDA
  • 20 February 2020 VAI US FDA
  • 21 December 2016 VAI US FDA
  • 27 March 2015 VAI US FDA
  • 29 September 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Tarapur, India 3005256484
Thane, India 3007005296
vapi 396 195valsad, India Not on file
Vapi, India Not on file

What they file, and where

Molecule Regulators Docs
Mometasone Furoate SFDA (Saudi Arabia), US FDA 5
Fluticasone Propionate SFDA (Saudi Arabia), US FDA 3
Benazepril US FDA 2
Cyclophosphamide US FDA 2
Deferiprone SFDA (Saudi Arabia), US FDA 2
Venlafaxine US FDA 2
Adapalene US FDA 1
Apixaban US FDA 1
Azathioprine US FDA 1
Bicalutamide US FDA 1
Show all 30 molecules on file
Budesonide US FDA 1
Bupropion US FDA 1
Caffeine US FDA 1
Capecitabine US FDA 1
Ciclesonide US FDA 1
Desonide US FDA 1
Diflunisal US FDA 1
Empagliflozin US FDA 1
Enzalutamide US FDA 1
Fluticasone Furoate US FDA 1
Ifosfamide US FDA 1
Ipratropium US FDA 1
Levosalbutamol US FDA 1
Loteprednol Etabonate US FDA 1
Mercaptopurine US FDA 1
Mesna US FDA 1
Mirabegron US FDA 1
Palbociclib US FDA 1
Phenylephrine US FDA 1
Quetiapine US FDA 1

Also appears on these molecule pages

Show 4 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 4 None
CDSCO (India) None 2
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $20.1M 44
2025 $242.7M $125.7M 72
2024 $221.4M $89.9M 72
2023 $235.6M $73.5M 70

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Aarti Pharmalabs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 March 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported